NCT07537881 2026-04-17
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Not yet recruiting
RemeGen Co., Ltd.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Chengdu Kanghong Biotech Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Leads Biolabs Co.,Ltd
University Medical Center Groningen
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
Sichuan Enray Pharmaceutical Sciences Company